BICYCLE THERAPEUTICS PLC
BCYCDrugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
This month
Market Overview
Stock performance and key metrics
3 upcoming, 0 past
BT5528 Phase 2 Est. Readout
Primary completion for BT5528 trial (NCT04180371) in Advanced Solid Tumor Historically Known for High EphA2 Expression
Source2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
BT8009
Urinary Bladder Neoplasm
Gemcitabine + cisplatin Or carboplatin
Metastatic Urothelial Cancer
Zelenectide pevedotin (BT8009)
Non-Small Cell Lung Cancer
BT5528
Advanced Solid Tumor Historically Known for High EphA2 Expression
BT7480
Advanced Solid Tumor
nuzefatide pevedotin (BT5528)
Pancreatic Ductal Adenocarcinoma (PDAC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BT8009 | Phase 3 | Urinary Bladder Neoplasm | - | - |
Gemcitabine + cisplatin Or carboplatin | Phase 3 | Metastatic Urothelial Cancer | - | - |
Zelenectide pevedotin (BT8009) | Phase 2 | Non-Small Cell Lung Cancer | - | - |
BT5528 | Phase 2 | Advanced Solid Tumor Historically Known for High EphA2 Expression | - | - |
BT7480 | Phase 2 | Advanced Solid Tumor | - | - |
nuzefatide pevedotin (BT5528) | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BICYCLE THERAPEUTICS PLC's drug pipeline?→
CatalystAlert tracks 6 drug candidates in BICYCLE THERAPEUTICS PLC's (BCYC) pipeline across Phase 3, Phase 2. Its lead program is BT8009 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BICYCLE THERAPEUTICS PLC's next FDA catalyst?→
BICYCLE THERAPEUTICS PLC's (BCYC) next tracked catalyst is a Phase 2 expected July 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BCYC biotech catalysts?→
Add BCYC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BICYCLE THERAPEUTICS PLC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.